Portal Innovations — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
CrossBridge Biocrossbridgebio.comOct 2024
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications.
BiotechHealthtechHouston, US
Kyoji Tsuchikama(Executive Officer, Director, Promoter)Michael Torres(Executive Officer, Director, Promoter)
BoardWilliam F. McKeon(Director)Damir Illich(Director)Patrick James Crutcher(Director)
Co-investorsTMC Venture Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.